Effect of Gliclazide or Gliclazide plus Metformin Combination on Glycemic Control in Patients with T2DM in India: A Real-World, Retrospective, Longitudinal, Observational Study from Electronic Medical Records.
Journal
Drugs - real world outcomes
ISSN: 2199-1154
Titre abrégé: Drugs Real World Outcomes
Pays: Switzerland
ID NLM: 101658456
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
11
7
2020
medline:
11
7
2020
entrez:
11
7
2020
Statut:
ppublish
Résumé
The efficacy of gliclazide has been reported in clinical trials in India. However, real-world data on the effectiveness of gliclazide in India is unavailable. To provide real-world evidence regarding the effectiveness of gliclazide or gliclazide + metformin fixed-dose combination or separate medications, used either as monotherapy or as the latest add-on to other antihyperglycemic agents in reducing glycated hemoglobin (HbA1c) levels in Indian patients with type 2 diabetes mellitus (T2DM). Electronic medical record data of adult patients who were diagnosed with T2DM who were newly initiated on or had been prescribed gliclazide or gliclazide + metformin combination for < 30 days as monotherapy or as add-on therapy to other antihyperglycemic agents, and had HbA1c ≥ 6.5% were retrospectively analyzed. Mean change in HbA1c from baseline was the primary endpoint. Secondary endpoints were assessment of dosages and formulations of gliclazide or gliclazide + metformin prescribed in the HbA1c spectrum and antihyperglycemic agents to which gliclazide or gliclazide + metformin was added as an adjunct. Readings were obtained before initiating gliclazide or gliclazide + metformin and after at least 90 days of treatment with gliclazide or gliclazide + metformin. Included patients (n = 498) were categorized into gliclazide only (n = 66), gliclazide + metformin only (n = 179), gliclazide add-on (n = 169), and gliclazide + metformin add-on (n = 84) groups. Mean (95% confidence interval [CI]) change in HbA1c among patients with baseline HbA1c > 7% was - 0.8% (- 1.26, - 0.34) in gliclazide only group; - 1.6% (- 1.89, - 1.31; p < 0.001) in gliclazide + metformin group; - 1.2% (- 1.50, - 0.90; p < 0.001) in add-on gliclazide group; and - 1.4% (- 1.75, - 1.05; p < 0.001) in add-on gliclazide + metformin group. Gliclazide once daily was the most prescribed regimen in the gliclazide only group (72.7%), with 60 mg being the most prescribed modified-release dose (62.5%). Gliclazide + metformin twice daily was the most prescribed regimen in the gliclazide + metformin group (69.3%) with 80 mg + 500 mg being the most prescribed immediate-release dose (62.9%). Gliclazide and gliclazide + metformin were most added as an adjunct to existing prescriptions of biguanides (83.4%) or insulin (64.3%), respectively. Gliclazide or gliclazide + metformin prescribed as mono- or add-on therapy during routine clinical practice effectively reduced HbA1c in Indian patients with T2DM, thus validating the use of gliclazide and gliclazide + metformin for managing T2DM in India.
Sections du résumé
BACKGROUND
BACKGROUND
The efficacy of gliclazide has been reported in clinical trials in India. However, real-world data on the effectiveness of gliclazide in India is unavailable.
OBJECTIVE
OBJECTIVE
To provide real-world evidence regarding the effectiveness of gliclazide or gliclazide + metformin fixed-dose combination or separate medications, used either as monotherapy or as the latest add-on to other antihyperglycemic agents in reducing glycated hemoglobin (HbA1c) levels in Indian patients with type 2 diabetes mellitus (T2DM).
METHODS
METHODS
Electronic medical record data of adult patients who were diagnosed with T2DM who were newly initiated on or had been prescribed gliclazide or gliclazide + metformin combination for < 30 days as monotherapy or as add-on therapy to other antihyperglycemic agents, and had HbA1c ≥ 6.5% were retrospectively analyzed. Mean change in HbA1c from baseline was the primary endpoint. Secondary endpoints were assessment of dosages and formulations of gliclazide or gliclazide + metformin prescribed in the HbA1c spectrum and antihyperglycemic agents to which gliclazide or gliclazide + metformin was added as an adjunct. Readings were obtained before initiating gliclazide or gliclazide + metformin and after at least 90 days of treatment with gliclazide or gliclazide + metformin.
RESULTS
RESULTS
Included patients (n = 498) were categorized into gliclazide only (n = 66), gliclazide + metformin only (n = 179), gliclazide add-on (n = 169), and gliclazide + metformin add-on (n = 84) groups. Mean (95% confidence interval [CI]) change in HbA1c among patients with baseline HbA1c > 7% was - 0.8% (- 1.26, - 0.34) in gliclazide only group; - 1.6% (- 1.89, - 1.31; p < 0.001) in gliclazide + metformin group; - 1.2% (- 1.50, - 0.90; p < 0.001) in add-on gliclazide group; and - 1.4% (- 1.75, - 1.05; p < 0.001) in add-on gliclazide + metformin group. Gliclazide once daily was the most prescribed regimen in the gliclazide only group (72.7%), with 60 mg being the most prescribed modified-release dose (62.5%). Gliclazide + metformin twice daily was the most prescribed regimen in the gliclazide + metformin group (69.3%) with 80 mg + 500 mg being the most prescribed immediate-release dose (62.9%). Gliclazide and gliclazide + metformin were most added as an adjunct to existing prescriptions of biguanides (83.4%) or insulin (64.3%), respectively.
CONCLUSION
CONCLUSIONS
Gliclazide or gliclazide + metformin prescribed as mono- or add-on therapy during routine clinical practice effectively reduced HbA1c in Indian patients with T2DM, thus validating the use of gliclazide and gliclazide + metformin for managing T2DM in India.
Identifiants
pubmed: 32648242
doi: 10.1007/s40801-020-00206-7
pii: 10.1007/s40801-020-00206-7
pmc: PMC7581661
doi:
Types de publication
Journal Article
Langues
eng
Pagination
271-279Références
J Basic Clin Pharm. 2014 Jun;5(3):79-83
pubmed: 25278671
Am J Kidney Dis. 2012 Nov;60(5):850-86
pubmed: 23067652
Indian J Endocrinol Metab. 2018 Jan-Feb;22(1):132-157
pubmed: 29535952
Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):40-45
pubmed: 31016151
Diabetes Obes Metab. 2006 Mar;8(2):184-91
pubmed: 16448522
J Assoc Physicians India. 2017 May;65(5):50-54
pubmed: 28598049
Diabetes Care. 2016 May;39(5):694-700
pubmed: 27006512
Global Health. 2014 Dec 02;10:80
pubmed: 25443136
Indian J Community Med. 2019 Apr-Jun;44(2):171-172
pubmed: 31333300
World J Diabetes. 2014 Dec 15;5(6):854-9
pubmed: 25512787
Cardiovasc Diabetol. 2018 Sep 27;17(1):129
pubmed: 30261876
Diabetes Care. 2019 Jan;42(Suppl 1):S90-S102
pubmed: 30559235
Open Ophthalmol J. 2014 Dec 31;8:91-4
pubmed: 25674186
Diabetes Technol Ther. 2008 Oct;10(5):363-8
pubmed: 18715212
Am J Ther. 2010 Nov-Dec;17(6):559-65
pubmed: 20093927
Diabetol Metab Syndr. 2018 Apr 10;10:30
pubmed: 29651307
BMC Med. 2019 May 13;17(1):92
pubmed: 31084606
Lancet Diabetes Endocrinol. 2015 Jan;3(1):43-51
pubmed: 25466239
Niger J Clin Pract. 2018 Mar;21(3):343-349
pubmed: 29519984
BMJ. 2011;343:d2304
pubmed: 22803193
Presse Med. 2004 Feb 14;33(3):156-60
pubmed: 15029026
Int J Environ Res Public Health. 2019 Jul 30;16(15):
pubmed: 31366085
J Fam Pract. 2016 Sep;65(9):587-93
pubmed: 27672684
J Assoc Physicians India. 2015 Dec;63(12):26-29
pubmed: 27666900
J Midlife Health. 2019 Apr-Jun;10(2):81-88
pubmed: 31391757
J Assoc Physicians India. 2017 Jun;65(6):38-41
pubmed: 28782312
Diabetes Metab Syndr. 2019 Jul - Aug;13(4):2469-2472
pubmed: 31405662
J Diabetes Complications. 2000 Jul-Aug;14(4):185-91
pubmed: 11004426
Patient Prefer Adherence. 2013 May 20;7:419-34
pubmed: 23737662
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
Diabetes Obes Metab. 2004 Nov;6(6):414-21
pubmed: 15479217
J Pharm Bioallied Sci. 2016 Jul-Sep;8(3):223-8
pubmed: 27413351
South Med J. 2002 Jan;95(1):68-71
pubmed: 11827247
N Engl J Med. 2008 Jun 12;358(24):2560-72
pubmed: 18539916
Ann Intern Med. 2013 Jun 4;158(11):825-30
pubmed: 23732715